To further investigate if the ZNF224 expression can be used to discriminate between low (Rai 0-Binet A) and medium/high risk (Rai I-IV, Binet B/C) of progression in patients with CLL, receiver operating characteristic curve (ROC) was used. Here, ZNF224 is linked to B-cell chronic lymphocytic leukemia.